大腸直腸癌診斷市場－策略分析與預測（2026-2035）

預計大腸直腸癌診斷市場將從 2026 年的 89.1 億美元成長到 2035 年的 198.1 億美元，複合年成長率為 9.3%。

大腸直腸癌的診斷是現代腫瘤學的關鍵環節，因為早期發現能夠顯著提高患者的存活率和治療效果。全球醫療衛生系統正在加強癌症篩檢工作，以期早期發現大腸癌並降低疾病相關死亡率。該市場涵蓋篩檢、疾病確診、分子譜分析、伴隨診斷、復發監測和治療方案等各個方面。人們對大腸直腸癌預防的認知不斷提高，篩檢指南的完善，以及人工智慧、液態生物檢體和基因組診斷技術的進步，正在改變臨床格局。診斷設備製造商正加大對創新技術的投資，以提高檢測準確性、加快檢測速度並增強患者依從性。

市場促進因素

擴大大規模健康篩檢計劃

由於早期發現是降低死亡率最有效的策略，各國政府和醫療機構不斷擴大大腸癌篩檢力道。糞便免疫化學檢查（FIT）、糞便DNA檢測和大腸鏡檢查等篩檢方法的日益普及，導致全球大腸癌診斷率不斷上升。

精準腫瘤學的廣泛應用

隨著精準醫療的進步，對分子和基因生物標記檢測的需求日益成長，以支持治療方案的選擇、伴隨診斷和個人化治療決策。隨著標靶治療的日益普及，對先進診斷平台的需求也持續成長。

過渡到微創檢測

醫療機構正擴大採用分子檢測技術，例如糞便樣本檢測、液態生物檢體和血液篩檢，以提高患者就醫便利性，同時減少對侵入性診斷程序的依賴。這些技術有望成為傳統大腸鏡檢查的補充，而非替代。

人工智慧（AI）的整合

人工智慧 (AI) 正在改善影像解讀、病理工作流程、診斷準確性和檢查室效率。 AI 驅動的診斷平台支援早期檢測，同時減少不同醫療機構間的診斷差異。

市場限制因素

先進分子診斷技術高成本

基因組檢測、液態生物檢體和次世代定序仍然相對昂貴，阻礙了它們在對成本敏感的醫療保健系統中廣泛應用。

發展中地區的進入限制

在許多新興市場，缺乏診斷檢查室、訓練有素的專業人員和篩檢基礎設施仍然是一個挑戰，限制了及時診斷大腸直腸癌的機會。

監管和檢驗要求

製造商必須進行廣泛的分析和臨床檢驗研究，新的診斷技術才能獲得監管部門的批准並在臨床實踐中廣泛應用。

目錄

第1章執行摘要

• 市場概述
• 主要分析結果
• 分析師意見
• 策略建議

第2章 分析方法

• 分析設計
• 資料收集和分析方法
• 市場規模估算
• 預測模型
• 先決條件和限制

第3章：大腸直腸癌診斷市場：概論、市場規模與預測

• 市場定義和範圍
• 疾病概述
• 產業變化
• 主要市場趨勢
• 市場規模表現分析
• 市場預測分析
• 疾病負擔與未滿足的需求
• 流行病學和盛行率分析
• 已確診患者族群的分析
• 篩檢和檢測量分析
• 患者治療進展分析
• 大腸直腸癌篩檢現狀
• 腫瘤詳細診斷概述

第4章 市場動態

• 市場促進因素
• 市場限制因素
• 市場機遇
• 市場挑戰

第5章 行業情勢

• 產業價值鏈分析
• 定價分析
• 還款狀態

第6章：創新趨勢

• 大腸直腸癌診斷領域的新興技術
• 產品創新分析
• 液態生物檢體進展
• 分子和基因生物標記的進展
• 多種癌症的早期檢測技術
• 臨床試驗分析
• 管道分析
• 人工智慧在大腸直腸癌篩檢的應用
• 數位病理學與診斷工作流程的整合
• 技術藍圖

第7章 監理情勢

• 法律規範
• 核准流程
• 合規要求

第8章：大腸直腸癌診斷市場：展望分析

• 分析：按技術平台
• 分析：依生物標記類型
• 分析：依樣本類型
• 分析：透過臨床應用
• 分析：透過分析方法
• 分析：篩檢試驗與診斷試驗的比較
• 分析：按最終用戶

第9章：大腸直腸癌診斷市場：細分市場分析

• 按產品/服務
  • 裝置
  • 試劑和耗材
  • 軟體和診斷分析解決方案
  • 診斷檢測服務
• 透過診斷技術
  • 糞便免疫化學檢查（FIT）
  • 癒創木脂法大便潛血試驗（gFOBT）
  • 糞便DNA檢測
  • 根據大腸鏡檢查結果進行診斷
  • 乙狀結腸鏡檢查
  • CT結腸成像
  • 分子和基因組檢測
  • 液態生物檢體
• 透過使用
  • 篩檢和早期檢測
  • 疾病的診斷和確診
  • 預後評估
  • 治療方案、伴隨診斷
  • 復發監測
• 最終用戶
  • 醫院
  • 診斷檢查室
  • 癌症中心
  • 學術研究機構
  • 其他最終用戶

第10章：大腸直腸癌診斷市場：區域分析

• 北美洲
• 歐洲
• 亞太地區
• 南美洲
• 中東和非洲

第11章：大腸直腸癌診斷市場：國別分析

• 美國
• 加拿大
• 德國
• 英國
• 法國
• 義大利
• 西班牙
• 荷蘭
• 中國
• 日本
• 韓國
• 澳洲
• 印度
• 巴西
• 沙烏地阿拉伯

第12章 競爭格局

• 市佔率分析
• 策略趨勢
• 企業合併、商業夥伴關係和合作
• 新產品發布

第13章：公司簡介

• Exact Sciences Corporation
• Guardant Health, Inc.
• F. Hoffmann-La Roche Ltd
• QIAGEN NV
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Bio-Rad Laboratories, Inc.
• Sysmex Corporation
• Epigenomics AG
• Freenome Holdings, Inc.
• Geneoscopy, Inc.
• Novigenix SA
• Mainz Biomed NV
• Eiken Chemical Co., Ltd.

第14章：大腸直腸癌診斷市場：商業預測分析

第15章：投資與資金籌措分析

• 創業投資趨勢
• 政府資金
• 研發投資

第16章：未來展望

• 主要成長機遇
• 未來產業趨勢

The Colorectal Cancer Diagnostics Market is anticipated to grow at a CAGR of 9.3% from USD 8.91 billion in 2026 to USD 19.81 billion in 2035.

Colorectal cancer diagnostics have become an essential component of modern oncology as early detection significantly improves patient survival and treatment outcomes. Healthcare systems worldwide are strengthening cancer screening initiatives to identify colorectal cancer at earlier stages while reducing disease-related mortality. The market encompasses screening, disease confirmation, molecular profiling, companion diagnostics, recurrence monitoring, and treatment selection. Growing awareness of colorectal cancer prevention, favorable screening guidelines, and advancements in artificial intelligence, liquid biopsy, and genomic diagnostics continue to transform clinical practice. Diagnostic manufacturers are increasingly investing in innovative technologies that deliver greater accuracy, faster turnaround times, and improved patient compliance.

Market Drivers

Expansion of Population Screening Programs

Governments and healthcare organizations continue expanding colorectal cancer screening initiatives as early detection remains the most effective strategy for reducing mortality. Growing adoption of fecal immunochemical tests (FIT), stool DNA tests, and colonoscopy-based screening is increasing diagnostic volumes globally.

Growing Adoption of Precision Oncology

Precision medicine is increasing the need for molecular and genomic biomarker testing to support treatment selection, companion diagnostics, and personalized therapeutic decisions. As targeted therapies become more common, demand for advanced diagnostic platforms continues to rise.

Shift Toward Minimally Invasive Testing

Healthcare providers are increasingly adopting stool-based molecular testing, liquid biopsy, and blood-based screening technologies to improve patient participation while reducing reliance on invasive diagnostic procedures. These technologies are expected to complement traditional colonoscopy rather than replace it.

Artificial Intelligence Integration

Artificial intelligence is improving image interpretation, pathology workflows, diagnostic accuracy, and laboratory efficiency. AI-assisted diagnostic platforms are supporting earlier detection while reducing diagnostic variability across healthcare settings.

Market Restraints

High Cost of Advanced Molecular Diagnostics

Genomic testing, liquid biopsy, and next-generation sequencing remain relatively expensive, limiting widespread adoption in cost-sensitive healthcare systems.

Limited Access in Developing Regions

Many emerging markets continue facing shortages of diagnostic laboratories, trained specialists, and screening infrastructure, restricting access to timely colorectal cancer diagnosis.

Regulatory and Validation Requirements

Manufacturers must conduct extensive analytical and clinical validation studies before new diagnostic technologies receive regulatory approval and broad clinical adoption.

Market and Technology Insights

The global colorectal cancer diagnostics market can be segmented by product & service, diagnostic technology, application, end user, and geography.

By product & service, the market includes instruments, reagents & consumables, software & diagnostic analytics solutions, and diagnostic testing services. Reagents and consumables continue to account for a substantial share because of recurring laboratory testing demand.

By diagnostic technology, the market comprises fecal immunochemical tests (FIT), guaiac fecal occult blood tests (gFOBT), stool DNA testing, colonoscopy-based diagnostics, flexible sigmoidoscopy, CT colonography, molecular and genomic testing, and liquid biopsy testing. Molecular diagnostics and liquid biopsy technologies are expected to experience rapid growth as precision oncology expands.

By application, diagnostics support screening and early detection, diagnosis and disease confirmation, prognostic assessment, treatment selection and companion diagnostics, and recurrence monitoring. Screening remains the largest application owing to increasing preventive healthcare initiatives worldwide.

By end user, the market includes hospitals, diagnostic laboratories, cancer centers, academic & research institutes, and other healthcare facilities. Diagnostic laboratories continue expanding molecular testing capacity to accommodate increasing screening volumes.

Market Trends

The colorectal cancer diagnostics market continues evolving through technological innovation.

Key trends include:

• Expansion of stool-based screening programs.
• Rapid development of liquid biopsy technologies.
• Increasing use of molecular and genomic biomarkers.
• Artificial intelligence integration into pathology and imaging.
• Growing adoption of companion diagnostics.
• Expansion of multi-cancer early detection technologies.
• Greater laboratory automation and digital workflow integration.

Regional Insights

North America remains the largest colorectal cancer diagnostics market because of extensive screening programs, advanced healthcare infrastructure, favorable reimbursement, and widespread adoption of precision oncology technologies.

Europe continues to maintain a significant market share through organized national screening initiatives, standardized clinical guidelines, and increasing molecular diagnostic adoption.

Asia-Pacific is expected to register the fastest growth owing to increasing cancer incidence, improving healthcare infrastructure, expanding diagnostic capacity, and rising government investment in preventive oncology. China, Japan, India, South Korea, and Australia are major contributors to regional growth.

Latin America and the Middle East & Africa are gradually expanding colorectal cancer screening through healthcare modernization and improved diagnostic accessibility.

Competitive Landscape

The market consists of global diagnostics manufacturers, molecular diagnostics companies, laboratory service providers, and biotechnology firms. Companies continue investing in molecular diagnostics, liquid biopsy platforms, companion diagnostics, artificial intelligence, and digital pathology solutions to strengthen their competitive positions. Strategic collaborations, acquisitions, and product launches remain central to market expansion.

Major companies include Exact Sciences Corporation, Guardant Health Inc., F. Hoffmann-La Roche Ltd., QIAGEN N.V., Abbott Laboratories, Thermo Fisher Scientific Inc., Danaher Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Epigenomics AG, Freenome Holdings Inc., Geneoscopy Inc., Novigenix SA, Mainz Biomed N.V., and Eiken Chemical Co., Ltd.

Future Outlook

The future of the colorectal cancer diagnostics market will increasingly focus on earlier, less invasive detection supported by molecular diagnostics, liquid biopsy, artificial intelligence, and multi-omics technologies. Growing integration of precision oncology into routine clinical practice will continue increasing demand for genomic characterization and companion diagnostics. Continued investment in blood-based screening technologies and digital diagnostic workflows is expected to improve patient participation while enhancing diagnostic accuracy and healthcare efficiency.

Conclusion

The Global Colorectal Cancer Diagnostics Market is expected to experience strong growth through 2035, supported by expanding screening initiatives, increasing precision medicine adoption, and rapid technological innovation. Although cost, regulatory requirements, and healthcare infrastructure disparities remain important challenges, advances in molecular diagnostics, liquid biopsy, artificial intelligence, and personalized oncology are expected to create substantial opportunities for diagnostic manufacturers, healthcare providers, laboratories, researchers, and investors.

Key Benefits of this Report

• Comprehensive assessment of the global colorectal cancer diagnostics market.
• Detailed evaluation of diagnostic technologies, molecular innovations, and market trends.
• Analysis of competitive strategies, regulatory developments, and commercialization opportunities.
• Insights into precision oncology, liquid biopsy, and AI-driven diagnostic advancements.
• Valuable resource for diagnostic manufacturers, biotechnology companies, laboratories, healthcare providers, researchers, investors, and policymakers.

What Businesses Use Our Reports For

Market opportunity assessment, product portfolio planning, competitive benchmarking, commercialization strategy, investment analysis, partnership evaluation, regulatory planning, laboratory expansion, and long-term strategic decision-making.

Report Coverage

• Historical data from 2021 to 2024, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global colorectal cancer diagnostics market by product & service, diagnostic technology, application, end user, and geography
• Evaluation of market dynamics, technological innovations, competitive landscape, regulatory environment, and future growth opportunities
• Assessment of molecular diagnostics, liquid biopsy, precision oncology, AI integration, digital pathology, companion diagnostics, and commercialization strategies
• Analysis of FIT, gFOBT, stool DNA testing, colonoscopy-based diagnostics, flexible sigmoidoscopy, CT colonography, molecular and genomic testing, liquid biopsy testing, diagnostic services, and emerging colorectal cancer diagnostic technologies through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Colorectal Cancer Diagnostics Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Disease Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast Analysis (2026-2035)
• 3.7 Disease Burden and Unmet Diagnostic Needs
• 3.8 Epidemiology and Prevalence Analysis
• 3.9 Diagnosed Patient Population Analysis
• 3.10 Screening and Testing Volume Analysis
• 3.11 Patient Journey Analysis
• 3.12 Colorectal Cancer Screening Landscape
• 3.13 Precision Oncology Diagnostics Overview

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies in Colorectal Cancer Diagnostics
• 6.2 Product Innovation Analysis
• 6.3 Liquid Biopsy Advancements
• 6.4 Molecular and Genomic Biomarker Developments
• 6.5 Multi-Cancer Early Detection Technologies
• 6.6 Clinical Trial Analysis
• 6.7 Pipeline Analysis
• 6.8 AI Integration in Colorectal Cancer Detection
• 6.9 Digital Pathology and Diagnostic Workflow Integration
• 6.10 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Colorectal Cancer Diagnostics Market Landscape Analysis

• 8.1 Analysis by Technology Platform
• 8.2 Analysis by Biomarker Type
• 8.3 Analysis by Sample Type
• 8.4 Analysis by Clinical Application
• 8.5 Analysis by Testing Methodology
• 8.6 Analysis by Screening versus Diagnostic Testing
• 8.7 Analysis by End User

9. Colorectal Cancer Diagnostics Market Segment Analysis (2021-2035)

• 9.1 By Product & Service
  • 9.1.1 Instruments
  • 9.1.2 Reagents & Consumables
  • 9.1.3 Software & Diagnostic Analytics Solutions
  • 9.1.4 Diagnostic Testing Services
• 9.2 By Diagnostic Technology
  • 9.2.1 Fecal Immunochemical Test (FIT)
  • 9.2.2 Guaiac Fecal Occult Blood Test (gFOBT)
  • 9.2.3 Stool DNA Testing
  • 9.2.4 Colonoscopy-Based Diagnostics
  • 9.2.5 Flexible Sigmoidoscopy
  • 9.2.6 CT Colonography
  • 9.2.7 Molecular and Genomic Testing
  • 9.2.8 Liquid Biopsy Testing
• 9.3 By Application
  • 9.3.1 Screening and Early Detection
  • 9.3.2 Diagnosis and Disease Confirmation
  • 9.3.3 Prognostic Assessment
  • 9.3.4 Treatment Selection and Companion Diagnostics
  • 9.3.5 Recurrence Monitoring
• 9.4 By End User
  • 9.4.1 Hospitals
  • 9.4.2 Diagnostic Laboratories
  • 9.4.3 Cancer Centers
  • 9.4.4 Academic & Research Institutes
  • 9.4.5 Other End Users

10. Colorectal Cancer Diagnostics Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Colorectal Cancer Diagnostics Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Netherlands
• 11.9 China
• 11.10 Japan
• 11.11 South Korea
• 11.12 Australia
• 11.13 India
• 11.14 Brazil
• 11.15 Saudi Arabia

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 Exact Sciences Corporation
• 13.2 Guardant Health, Inc.
• 13.3 F. Hoffmann-La Roche Ltd
• 13.4 QIAGEN N.V.
• 13.5 Abbott Laboratories
• 13.6 Thermo Fisher Scientific Inc.
• 13.7 Danaher Corporation
• 13.8 Bio-Rad Laboratories, Inc.
• 13.9 Sysmex Corporation
• 13.10 Epigenomics AG
• 13.11 Freenome Holdings, Inc.
• 13.12 Geneoscopy, Inc.
• 13.13 Novigenix SA
• 13.14 Mainz Biomed N.V.
• 13.15 Eiken Chemical Co., Ltd.

14. Colorectal Cancer Diagnostics Market Commercial Forecast Analysis

• 14.1 Forecast by Instruments
• 14.2 Forecast by Reagents & Consumables
• 14.3 Forecast by Software & Diagnostic Analytics Solutions
• 14.4 Forecast by Diagnostic Testing Services
• 14.5 Forecast by Stool-Based Testing
• 14.6 Forecast by Colonoscopy-Based Diagnostics
• 14.7 Forecast by Molecular and Genomic Testing
• 14.8 Forecast by Liquid Biopsy Testing

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends